| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/APT.13081 |
| P698 | PubMed publication ID | 25619871 |
| P2093 | author name string | A Ahmed | |
| H Park | |||
| S Saab | |||
| Z M Younossi | |||
| D Dieterich | |||
| S C Gordon | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Hepatitis C virus | Q708693 |
| sofosbuvir | Q2502747 | ||
| ledipasvir | Q15409409 | ||
| chronic hepatitis C | Q55779873 | ||
| P304 | page(s) | 544-563 | |
| P577 | publication date | 2015-01-26 | |
| P1433 | published in | Alimentary Pharmacology & Therapeutics | Q4726656 |
| P1476 | title | Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection | |
| P478 | volume | 41 |
| Q35915999 | A Budget Impact Analysis of Newly Available Hepatitis C Therapeutics and the Financial Burden on a State Correctional System |
| Q37629097 | A Cost-Utility Analysis of Different Antiviral Medicine Regimens in Patients With Chronic Hepatitis C Virus Genotype 1 Infection |
| Q40888934 | A Phase I Dose Escalation Study Demonstrates Quercetin Safety and Explores Potential for Bioflavonoid Antivirals in Patients with Chronic Hepatitis C. |
| Q48229562 | Acanthoic acid suppresses lipin1/2 via TLR4 and IRAK4 signalling pathways in EtOH- and lipopolysaccharide-induced hepatic lipogenesis. |
| Q37018850 | Accessibility to Oral Antiviral Therapy for Patients with Chronic Hepatitis C in the United States |
| Q33861095 | Activation of hepatic stellate cells by the ubiquitin C-terminal hydrolase 1 protein secreted from hepatitis C virus-infected hepatocytes. |
| Q39883996 | An In-Depth Analysis of Patient-Reported Outcomes in Patients With Chronic Hepatitis C Treated With Different Anti-Viral Regimens |
| Q39973981 | Applicability of Hepatitis C Virus RNA Viral Load Thresholds for 8-Week Treatments in Patients With Chronic Hepatitis C Virus Genotype 1 Infection. |
| Q42048758 | Assessing the Effect of Potential Reductions in Non-Hepatic Mortality on the Estimated Cost-Effectiveness of Hepatitis C Treatment in Early Stages of Liver Disease |
| Q38980602 | Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: The quality-adjusted cost of care |
| Q36444618 | Budget impact analysis of sofosbuvir-based regimens for the treatment of HIV/HCV-coinfected patients in northern Italy: a multicenter regional simulation |
| Q40197476 | Budget impact and cost-effectiveness analyses of direct-acting antivirals for chronic hepatitis C virus infection in Hong Kong. |
| Q38932103 | Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa. |
| Q40637339 | Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States |
| Q36238515 | Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany |
| Q52653977 | Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France. |
| Q40302226 | Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: Treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis. |
| Q40720905 | Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US. |
| Q55280669 | Cost-effectiveness of diagnostic and therapeutic interventions for chronic hepatitis C: a systematic review of model-based analyses. |
| Q40224995 | Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong |
| Q40546478 | Cost-utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan |
| Q54254113 | Cost/Benefit of Hepatitis C Treatment: It Does Not End with SVR. |
| Q45326148 | Direct medical costs associated with the extrahepatic manifestations of hepatitis C virus infection in France. |
| Q40129813 | Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients. |
| Q57066937 | Elimination of Hepatitis C in Liver Transplant Recipients |
| Q36336005 | Estimating cost-effectiveness associated with all-oral regimen for chronic hepatitis C in China |
| Q88724024 | Healthcare Cost and Utilization in Nonalcoholic Fatty Liver Disease: Real-World Data From a Large U.S. Claims Database |
| Q59349780 | Healthcare value of implementing hepatitis C screening in the adult general population in Spain |
| Q37578288 | Hepatitis C Virus: A Review of Treatment Guidelines, Cost-effectiveness, and Access to Therapy |
| Q57167190 | Hepatitis C in Lebanon: the burden of the disease and the value of comprehensive screening and treatment |
| Q56980591 | Impact of all-oral direct-acting antivirals on clinical and economic outcomes in chronic hepatitis C patients in the U.S |
| Q47605707 | Impact of ledipasvir/sofosbuvir on the work productivity of genotype 1 chronic hepatitis C patients in Asia |
| Q38663336 | Improved Hepascore in hepatitis C predicts reversal in risk of adverse outcome |
| Q40118666 | In an era of highly effective treatment, hepatitis C screening of the United States general population should be considered |
| Q37135584 | Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future |
| Q34470061 | Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C. |
| Q39462995 | Medical resource utilization and costs among Australian patients with genotype 1 chronic hepatitis C: results of a retrospective observational study |
| Q40576603 | Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis |
| Q30376341 | Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors - Results from the PAN Study. |
| Q30393824 | Patient-reported and economic outcomes related to sofosbuvir and ledipasvir treatment for chronic hepatitis C. |
| Q40312314 | Potential of Cannabidiol for the Treatment of Viral Hepatitis |
| Q40562865 | Prevention of progression to cirrhosis in hepatitis C with fibrosis: effectiveness and cost effectiveness of sequential therapy with new direct-acting anti-virals. |
| Q36948099 | Real-World Sustained Virologic Response Rates of Sofosbuvir-Containing Regimens in Patients Coinfected With Hepatitis C and HIV. |
| Q33621614 | Sofosbuvir-based Regimens with Task Shifting Is Cost-effective in Expanding Hepatitis C Treatment Access in the United States |
| Q39177479 | Spending on Hepatitis C Antivirals in the United States, 2009-2015. |
| Q38691333 | Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals |
| Q57307361 | The Effectiveness and Cost-Effectiveness of Hepatitis C Screening for Migrants in the EU/EEA: A Systematic Review |
| Q38563358 | The cost-effectiveness of novel direct acting antiviral agent therapies for the treatment of chronic hepatitis C. |
| Q39137372 | The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naïve and treatment-experienced) subjects treated with all-oral elbasvir/grazoprevir regimens in the United States. |
| Q39471203 | The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe |
| Q40567336 | The efficacy and safety of direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infection |
| Q38982462 | The impact of hepatitis C virus outside the liver: Evidence from Asia. |
| Q91656324 | The price of shortening anti-hepatitis C virus therapy: Is this truly cost saving? |
| Q38996459 | The value of cure associated with treating treatment-naïve chronic hepatitis C genotype 1: Are the new all-oral regimens good value to society? |
| Q38405059 | Transformation of hepatitis C antiviral treatment in a national healthcare system following the introduction of direct antiviral agents. |
| Q47546983 | Use of direct-acting antiviral agents in hepatitis C virus-infected liver transplant candidates |
| Q28072257 | Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence |
| Q91656302 | What is the ethical responsibility of a provider when prescribing the new direct-acting antiviral agents to patients with hepatitis C infection? |
| Q36075161 | Why We Should Be Willing to Pay for Hepatitis C Treatment |
| Q28550101 | Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data |
Search more.